Cypherpunk Technologies Inc. (FRA:5MC)

Germany flag Germany · Delayed Price · Currency is EUR
0.7250
-0.0300 (-3.97%)
Jan 23, 2026, 4:00 PM EST
40.78%
Market Cap35.54M -70.6%
Revenue (ttm)n/a
Net Income-43.51M
EPS-1.05
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume715
Open0.7250
Previous Close0.7550
Day's Range0.7250 - 0.7250
52-Week Range0.0280 - 3.0000
Betan/a
RSI34.18
Earnings DateMar 23, 2026

About Cypherpunk Technologies

Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGe... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2011
Employees 27
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 5MC
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements